Chapter 1 Industry Overview

1.1 Definition

1.2 Assumptions

1.3 Research Scope

1.4 Market Analysis by Regions

1.4.1 North America Market States and Outlook (2022-2027)

1.4.2 East Asia Market States and Outlook (2022-2027)

1.4.3 Europe Market States and Outlook (2022-2027)

1.4.4 South Asia Market States and Outlook (2022-2027)

1.4.5 Southeast Asia Market States and Outlook (2022-2027)

1.4.6 Middle East Market States and Outlook (2022-2027)

1.4.7 Africa Market States and Outlook (2022-2027)

1.4.8 Oceania Market States and Outlook (2022-2027)

1.4.9 South America Market States and Outlook (2022-2027)

1.5 Global PD-1/PD-L1 Immunotherapy Market Size Analysis from 2022 to 2027

1.5.1 Global PD-1/PD-L1 Immunotherapy Market Size Analysis from 2022 to 2027 by Consumption Volume

1.5.2 Global PD-1/PD-L1 Immunotherapy Market Size Analysis from 2022 to 2027 by Value

1.5.3 Global PD-1/PD-L1 Immunotherapy Price Trends Analysis from 2022 to 2027

1.6 COVID-19 Outbreak: PD-1/PD-L1 Immunotherapy Industry Impact

Chapter 2 Global PD-1/PD-L1 Immunotherapy Competition by Types, Applications, and Top Regions and Countries

2.1 Global PD-1/PD-L1 Immunotherapy (Volume and Value) by Type

2.1.1 Global PD-1/PD-L1 Immunotherapy Consumption and Market Share by Type (2016-2021)

2.1.2 Global PD-1/PD-L1 Immunotherapy Revenue and Market Share by Type (2016-2021)

2.2 Global PD-1/PD-L1 Immunotherapy (Volume and Value) by Application

2.2.1 Global PD-1/PD-L1 Immunotherapy Consumption and Market Share by Application (2016-2021)

2.2.2 Global PD-1/PD-L1 Immunotherapy Revenue and Market Share by Application (2016-2021)

2.3 Global PD-1/PD-L1 Immunotherapy (Volume and Value) by Regions

2.3.1 Global PD-1/PD-L1 Immunotherapy Consumption and Market Share by Regions (2016-2021)

2.3.2 Global PD-1/PD-L1 Immunotherapy Revenue and Market Share by Regions (2016-2021)

Chapter 3 Production Market Analysis

3.1 Global Production Market Analysis

3.1.1 2016-2021 Global Capacity, Production, Capacity Utilization Rate, Ex-Factory Price, Revenue, Cost, Gross and Gross Margin Analysis

3.1.2 2016-2021 Major Manufacturers Performance and Market Share

3.2 Regional Production Market Analysis

3.2.1 2016-2021 Regional Market Performance and Market Share

3.2.2 North America Market

3.2.3 East Asia Market

3.2.4 Europe Market

3.2.5 South Asia Market

3.2.6 Southeast Asia Market

3.2.7 Middle East Market

3.2.8 Africa Market

3.2.9 Oceania Market

3.2.10 South America Market

3.2.11 Rest of the World Market

Chapter 4 Global PD-1/PD-L1 Immunotherapy Sales, Consumption, Export, Import by Regions (2016-2021)

4.1 Global PD-1/PD-L1 Immunotherapy Consumption by Regions (2016-2021)

4.2 North America PD-1/PD-L1 Immunotherapy Sales, Consumption, Export, Import (2016-2021)

4.3 East Asia PD-1/PD-L1 Immunotherapy Sales, Consumption, Export, Import (2016-2021)

4.4 Europe PD-1/PD-L1 Immunotherapy Sales, Consumption, Export, Import (2016-2021)

4.5 South Asia PD-1/PD-L1 Immunotherapy Sales, Consumption, Export, Import (2016-2021)

4.6 Southeast Asia PD-1/PD-L1 Immunotherapy Sales, Consumption, Export, Import (2016-2021)

4.7 Middle East PD-1/PD-L1 Immunotherapy Sales, Consumption, Export, Import (2016-2021)

4.8 Africa PD-1/PD-L1 Immunotherapy Sales, Consumption, Export, Import (2016-2021)

4.9 Oceania PD-1/PD-L1 Immunotherapy Sales, Consumption, Export, Import (2016-2021)

4.10 South America PD-1/PD-L1 Immunotherapy Sales, Consumption, Export, Import (2016-2021)

Chapter 5 North America PD-1/PD-L1 Immunotherapy Market Analysis

5.1 North America PD-1/PD-L1 Immunotherapy Consumption and Value Analysis

5.1.1 North America PD-1/PD-L1 Immunotherapy Market Under COVID-19

5.2 North America PD-1/PD-L1 Immunotherapy Consumption Volume by Types

5.3 North America PD-1/PD-L1 Immunotherapy Consumption Structure by Application

5.4 North America PD-1/PD-L1 Immunotherapy Consumption by Top Countries

5.4.1 United States PD-1/PD-L1 Immunotherapy Consumption Volume from 2016 to 2021

5.4.2 Canada PD-1/PD-L1 Immunotherapy Consumption Volume from 2016 to 2021

5.4.3 Mexico PD-1/PD-L1 Immunotherapy Consumption Volume from 2016 to 2021

Chapter 6 East Asia PD-1/PD-L1 Immunotherapy Market Analysis

6.1 East Asia PD-1/PD-L1 Immunotherapy Consumption and Value Analysis

6.1.1 East Asia PD-1/PD-L1 Immunotherapy Market Under COVID-19

6.2 East Asia PD-1/PD-L1 Immunotherapy Consumption Volume by Types

6.3 East Asia PD-1/PD-L1 Immunotherapy Consumption Structure by Application

6.4 East Asia PD-1/PD-L1 Immunotherapy Consumption by Top Countries

6.4.1 China PD-1/PD-L1 Immunotherapy Consumption Volume from 2016 to 2021

6.4.2 Japan PD-1/PD-L1 Immunotherapy Consumption Volume from 2016 to 2021

6.4.3 South Korea PD-1/PD-L1 Immunotherapy Consumption Volume from 2016 to 2021

Chapter 7 Europe PD-1/PD-L1 Immunotherapy Market Analysis

7.1 Europe PD-1/PD-L1 Immunotherapy Consumption and Value Analysis

7.1.1 Europe PD-1/PD-L1 Immunotherapy Market Under COVID-19

7.2 Europe PD-1/PD-L1 Immunotherapy Consumption Volume by Types

7.3 Europe PD-1/PD-L1 Immunotherapy Consumption Structure by Application

7.4 Europe PD-1/PD-L1 Immunotherapy Consumption by Top Countries

7.4.1 Germany PD-1/PD-L1 Immunotherapy Consumption Volume from 2016 to 2021

7.4.2 UK PD-1/PD-L1 Immunotherapy Consumption Volume from 2016 to 2021

7.4.3 France PD-1/PD-L1 Immunotherapy Consumption Volume from 2016 to 2021

7.4.4 Italy PD-1/PD-L1 Immunotherapy Consumption Volume from 2016 to 2021

7.4.5 Russia PD-1/PD-L1 Immunotherapy Consumption Volume from 2016 to 2021

7.4.6 Spain PD-1/PD-L1 Immunotherapy Consumption Volume from 2016 to 2021

7.4.7 Netherlands PD-1/PD-L1 Immunotherapy Consumption Volume from 2016 to 2021

7.4.8 Switzerland PD-1/PD-L1 Immunotherapy Consumption Volume from 2016 to 2021

7.4.9 Poland PD-1/PD-L1 Immunotherapy Consumption Volume from 2016 to 2021

Chapter 8 South Asia PD-1/PD-L1 Immunotherapy Market Analysis

8.1 South Asia PD-1/PD-L1 Immunotherapy Consumption and Value Analysis

8.1.1 South Asia PD-1/PD-L1 Immunotherapy Market Under COVID-19

8.2 South Asia PD-1/PD-L1 Immunotherapy Consumption Volume by Types

8.3 South Asia PD-1/PD-L1 Immunotherapy Consumption Structure by Application

8.4 South Asia PD-1/PD-L1 Immunotherapy Consumption by Top Countries

8.4.1 India PD-1/PD-L1 Immunotherapy Consumption Volume from 2016 to 2021

8.4.2 Pakistan PD-1/PD-L1 Immunotherapy Consumption Volume from 2016 to 2021

8.4.3 Bangladesh PD-1/PD-L1 Immunotherapy Consumption Volume from 2016 to 2021

Chapter 9 Southeast Asia PD-1/PD-L1 Immunotherapy Market Analysis

9.1 Southeast Asia PD-1/PD-L1 Immunotherapy Consumption and Value Analysis

9.1.1 Southeast Asia PD-1/PD-L1 Immunotherapy Market Under COVID-19

9.2 Southeast Asia PD-1/PD-L1 Immunotherapy Consumption Volume by Types

9.3 Southeast Asia PD-1/PD-L1 Immunotherapy Consumption Structure by Application

9.4 Southeast Asia PD-1/PD-L1 Immunotherapy Consumption by Top Countries

9.4.1 Indonesia PD-1/PD-L1 Immunotherapy Consumption Volume from 2016 to 2021

9.4.2 Thailand PD-1/PD-L1 Immunotherapy Consumption Volume from 2016 to 2021

9.4.3 Singapore PD-1/PD-L1 Immunotherapy Consumption Volume from 2016 to 2021

9.4.4 Malaysia PD-1/PD-L1 Immunotherapy Consumption Volume from 2016 to 2021

9.4.5 Philippines PD-1/PD-L1 Immunotherapy Consumption Volume from 2016 to 2021

9.4.6 Vietnam PD-1/PD-L1 Immunotherapy Consumption Volume from 2016 to 2021

9.4.7 Myanmar PD-1/PD-L1 Immunotherapy Consumption Volume from 2016 to 2021

Chapter 10 Middle East PD-1/PD-L1 Immunotherapy Market Analysis

10.1 Middle East PD-1/PD-L1 Immunotherapy Consumption and Value Analysis

10.1.1 Middle East PD-1/PD-L1 Immunotherapy Market Under COVID-19

10.2 Middle East PD-1/PD-L1 Immunotherapy Consumption Volume by Types

10.3 Middle East PD-1/PD-L1 Immunotherapy Consumption Structure by Application

10.4 Middle East PD-1/PD-L1 Immunotherapy Consumption by Top Countries

10.4.1 Turkey PD-1/PD-L1 Immunotherapy Consumption Volume from 2016 to 2021

10.4.2 Saudi Arabia PD-1/PD-L1 Immunotherapy Consumption Volume from 2016 to 2021

10.4.3 Iran PD-1/PD-L1 Immunotherapy Consumption Volume from 2016 to 2021

10.4.4 United Arab Emirates PD-1/PD-L1 Immunotherapy Consumption Volume from 2016 to 2021

10.4.5 Israel PD-1/PD-L1 Immunotherapy Consumption Volume from 2016 to 2021

10.4.6 Iraq PD-1/PD-L1 Immunotherapy Consumption Volume from 2016 to 2021

10.4.7 Qatar PD-1/PD-L1 Immunotherapy Consumption Volume from 2016 to 2021

10.4.8 Kuwait PD-1/PD-L1 Immunotherapy Consumption Volume from 2016 to 2021

10.4.9 Oman PD-1/PD-L1 Immunotherapy Consumption Volume from 2016 to 2021

Chapter 11 Africa PD-1/PD-L1 Immunotherapy Market Analysis

11.1 Africa PD-1/PD-L1 Immunotherapy Consumption and Value Analysis

11.1.1 Africa PD-1/PD-L1 Immunotherapy Market Under COVID-19

11.2 Africa PD-1/PD-L1 Immunotherapy Consumption Volume by Types

11.3 Africa PD-1/PD-L1 Immunotherapy Consumption Structure by Application

11.4 Africa PD-1/PD-L1 Immunotherapy Consumption by Top Countries

11.4.1 Nigeria PD-1/PD-L1 Immunotherapy Consumption Volume from 2016 to 2021

11.4.2 South Africa PD-1/PD-L1 Immunotherapy Consumption Volume from 2016 to 2021

11.4.3 Egypt PD-1/PD-L1 Immunotherapy Consumption Volume from 2016 to 2021

11.4.4 Algeria PD-1/PD-L1 Immunotherapy Consumption Volume from 2016 to 2021

11.4.5 Morocco PD-1/PD-L1 Immunotherapy Consumption Volume from 2016 to 2021

Chapter 12 Oceania PD-1/PD-L1 Immunotherapy Market Analysis

12.1 Oceania PD-1/PD-L1 Immunotherapy Consumption and Value Analysis

12.2 Oceania PD-1/PD-L1 Immunotherapy Consumption Volume by Types

12.3 Oceania PD-1/PD-L1 Immunotherapy Consumption Structure by Application

12.4 Oceania PD-1/PD-L1 Immunotherapy Consumption by Top Countries

12.4.1 Australia PD-1/PD-L1 Immunotherapy Consumption Volume from 2016 to 2021

12.4.2 New Zealand PD-1/PD-L1 Immunotherapy Consumption Volume from 2016 to 2021

Chapter 13 South America PD-1/PD-L1 Immunotherapy Market Analysis

13.1 South America PD-1/PD-L1 Immunotherapy Consumption and Value Analysis

13.1.1 South America PD-1/PD-L1 Immunotherapy Market Under COVID-19

13.2 South America PD-1/PD-L1 Immunotherapy Consumption Volume by Types

13.3 South America PD-1/PD-L1 Immunotherapy Consumption Structure by Application

13.4 South America PD-1/PD-L1 Immunotherapy Consumption Volume by Major Countries

13.4.1 Brazil PD-1/PD-L1 Immunotherapy Consumption Volume from 2016 to 2021

13.4.2 Argentina PD-1/PD-L1 Immunotherapy Consumption Volume from 2016 to 2021

13.4.3 Columbia PD-1/PD-L1 Immunotherapy Consumption Volume from 2016 to 2021

13.4.4 Chile PD-1/PD-L1 Immunotherapy Consumption Volume from 2016 to 2021

13.4.5 Venezuela PD-1/PD-L1 Immunotherapy Consumption Volume from 2016 to 2021

13.4.6 Peru PD-1/PD-L1 Immunotherapy Consumption Volume from 2016 to 2021

13.4.7 Puerto Rico PD-1/PD-L1 Immunotherapy Consumption Volume from 2016 to 2021

13.4.8 Ecuador PD-1/PD-L1 Immunotherapy Consumption Volume from 2016 to 2021

Chapter 14 Company Profiles and Key Figures in PD-1/PD-L1 Immunotherapy Business

14.1 AstraZeneca Plc

14.1.1 AstraZeneca Plc Company Profile

14.1.2 AstraZeneca Plc PD-1/PD-L1 Immunotherapy Product Specification

14.1.3 AstraZeneca Plc PD-1/PD-L1 Immunotherapy Production Capacity, Revenue, Price and Gross Margin (2016-2021)

14.2 Innovent Biologics, Inc.

14.2.1 Innovent Biologics, Inc. Company Profile

14.2.2 Innovent Biologics, Inc. PD-1/PD-L1 Immunotherapy Product Specification

14.2.3 Innovent Biologics, Inc. PD-1/PD-L1 Immunotherapy Production Capacity, Revenue, Price and Gross Margin (2016-2021)

14.3 Chia Tai Tianqing Pharmaceutical Group Co. Ltd.

14.3.1 Chia Tai Tianqing Pharmaceutical Group Co. Ltd. Company Profile

14.3.2 Chia Tai Tianqing Pharmaceutical Group Co. Ltd. PD-1/PD-L1 Immunotherapy Product Specification

14.3.3 Chia Tai Tianqing Pharmaceutical Group Co. Ltd. PD-1/PD-L1 Immunotherapy Production Capacity, Revenue, Price and Gross Margin (2016-2021)

14.4 BeiGene, Ltd.

14.4.1 BeiGene, Ltd. Company Profile

14.4.2 BeiGene, Ltd. PD-1/PD-L1 Immunotherapy Product Specification

14.4.3 BeiGene, Ltd. PD-1/PD-L1 Immunotherapy Production Capacity, Revenue, Price and Gross Margin (2016-2021)

14.5 GlaxoSmithKline plc

14.5.1 GlaxoSmithKline plc Company Profile

14.5.2 GlaxoSmithKline plc PD-1/PD-L1 Immunotherapy Product Specification

14.5.3 GlaxoSmithKline plc PD-1/PD-L1 Immunotherapy Production Capacity, Revenue, Price and Gross Margin (2016-2021)

14.6 Bristol-Myers Squibb Company

14.6.1 Bristol-Myers Squibb Company Company Profile

14.6.2 Bristol-Myers Squibb Company PD-1/PD-L1 Immunotherapy Product Specification

14.6.3 Bristol-Myers Squibb Company PD-1/PD-L1 Immunotherapy Production Capacity, Revenue, Price and Gross Margin (2016-2021)

14.7 Merck & Co., Inc.

14.7.1 Merck & Co., Inc. Company Profile

14.7.2 Merck & Co., Inc. PD-1/PD-L1 Immunotherapy Product Specification

14.7.3 Merck & Co., Inc. PD-1/PD-L1 Immunotherapy Production Capacity, Revenue, Price and Gross Margin (2016-2021)

14.8 F. Hoffmann-La Roche Ltd

14.8.1 F. Hoffmann-La Roche Ltd Company Profile

14.8.2 F. Hoffmann-La Roche Ltd PD-1/PD-L1 Immunotherapy Product Specification

14.8.3 F. Hoffmann-La Roche Ltd PD-1/PD-L1 Immunotherapy Production Capacity, Revenue, Price and Gross Margin (2016-2021)

14.9 Eli Lilly & Company

14.9.1 Eli Lilly & Company Company Profile

14.9.2 Eli Lilly & Company PD-1/PD-L1 Immunotherapy Product Specification

14.9.3 Eli Lilly & Company PD-1/PD-L1 Immunotherapy Production Capacity, Revenue, Price and Gross Margin (2016-2021)

14.10 Jiangsu HengRui Medicine Co., Ltd.

14.10.1 Jiangsu HengRui Medicine Co., Ltd. Company Profile

14.10.2 Jiangsu HengRui Medicine Co., Ltd. PD-1/PD-L1 Immunotherapy Product Specification

14.10.3 Jiangsu HengRui Medicine Co., Ltd. PD-1/PD-L1 Immunotherapy Production Capacity, Revenue, Price and Gross Margin (2016-2021)

14.11 Novartis AG

14.11.1 Novartis AG Company Profile

14.11.2 Novartis AG PD-1/PD-L1 Immunotherapy Product Specification

14.11.3 Novartis AG PD-1/PD-L1 Immunotherapy Production Capacity, Revenue, Price and Gross Margin (2016-2021)

14.12 Sanofi S.A.

14.12.1 Sanofi S.A. Company Profile

14.12.2 Sanofi S.A. PD-1/PD-L1 Immunotherapy Product Specification

14.12.3 Sanofi S.A. PD-1/PD-L1 Immunotherapy Production Capacity, Revenue, Price and Gross Margin (2016-2021)

14.13 Pfizer Inc.

14.13.1 Pfizer Inc. Company Profile

14.13.2 Pfizer Inc. PD-1/PD-L1 Immunotherapy Product Specification

14.13.3 Pfizer Inc. PD-1/PD-L1 Immunotherapy Production Capacity, Revenue, Price and Gross Margin (2016-2021)

14.14 Regeneron Pharmaceuticals Inc.

14.14.1 Regeneron Pharmaceuticals Inc. Company Profile

14.14.2 Regeneron Pharmaceuticals Inc. PD-1/PD-L1 Immunotherapy Product Specification

14.14.3 Regeneron Pharmaceuticals Inc. PD-1/PD-L1 Immunotherapy Production Capacity, Revenue, Price and Gross Margin (2016-2021)

Chapter 15 Global PD-1/PD-L1 Immunotherapy Market Forecast (2022-2027)

15.1 Global PD-1/PD-L1 Immunotherapy Consumption Volume, Revenue and Price Forecast (2022-2027)

15.1.1 Global PD-1/PD-L1 Immunotherapy Consumption Volume and Growth Rate Forecast (2022-2027)

15.1.2 Global PD-1/PD-L1 Immunotherapy Value and Growth Rate Forecast (2022-2027)

15.2 Global PD-1/PD-L1 Immunotherapy Consumption Volume, Value and Growth Rate Forecast by Region (2022-2027)

15.2.1 Global PD-1/PD-L1 Immunotherapy Consumption Volume and Growth Rate Forecast by Regions (2022-2027)

15.2.2 Global PD-1/PD-L1 Immunotherapy Value and Growth Rate Forecast by Regions (2022-2027)

15.2.3 North America PD-1/PD-L1 Immunotherapy Consumption Volume, Revenue and Growth Rate Forecast (2022-2027)

15.2.4 East Asia PD-1/PD-L1 Immunotherapy Consumption Volume, Revenue and Growth Rate Forecast (2022-2027)

15.2.5 Europe PD-1/PD-L1 Immunotherapy Consumption Volume, Revenue and Growth Rate Forecast (2022-2027)

15.2.6 South Asia PD-1/PD-L1 Immunotherapy Consumption Volume, Revenue and Growth Rate Forecast (2022-2027)

15.2.7 Southeast Asia PD-1/PD-L1 Immunotherapy Consumption Volume, Revenue and Growth Rate Forecast (2022-2027)

15.2.8 Middle East PD-1/PD-L1 Immunotherapy Consumption Volume, Revenue and Growth Rate Forecast (2022-2027)

15.2.9 Africa PD-1/PD-L1 Immunotherapy Consumption Volume, Revenue and Growth Rate Forecast (2022-2027)

15.2.10 Oceania PD-1/PD-L1 Immunotherapy Consumption Volume, Revenue and Growth Rate Forecast (2022-2027)

15.2.11 South America PD-1/PD-L1 Immunotherapy Consumption Volume, Revenue and Growth Rate Forecast (2022-2027)

15.3 Global PD-1/PD-L1 Immunotherapy Consumption Volume, Revenue and Price Forecast by Type (2022-2027)

15.3.1 Global PD-1/PD-L1 Immunotherapy Consumption Forecast by Type (2022-2027)

15.3.2 Global PD-1/PD-L1 Immunotherapy Revenue Forecast by Type (2022-2027)

15.3.3 Global PD-1/PD-L1 Immunotherapy Price Forecast by Type (2022-2027)

15.4 Global PD-1/PD-L1 Immunotherapy Consumption Volume Forecast by Application (2022-2027)

15.5 PD-1/PD-L1 Immunotherapy Market Forecast Under COVID-19

Chapter 16 Conclusions

Research Methodology